Presented in U.S.Dollars Unaudited - Prepared by Management

	Mar 31	
	2021	
Assets		
Current Assets Cash and Equivalents	\$	64
Total Current Assets	\$	64
Deposits	\$	3,164
License Agreement, Net of Amortization		
Service Agreement from Owner	\$	-
Patents, Net of Amortization	\$	-
Total Assets	\$	3,228
Liabilities and Stockholders' Equity		
Current Liabilities Accounts Payable	\$	34,95,584
Accrued Interest	\$	-
License Agreement Payable	\$	-
Share application funds pending issuance authorization	\$	3,09,760
Loans from Co- Founders Loans from Officers / Directors Loans - Other	\$ \$ \$	- - 25,000
Total Current Liabilities	\$	38,30,344
Total Liabilities	\$	38,30,344
Stockholders' Equity		
Common Stock, no par value 10,000,000 shares authorized, 2,596,152 issued and outstanding at June 30, 2012 Preferred Stock, no par value 2,906,873 shares issued and outstanding at September 30, 2008 including shares issued for \$1,000,000 of future research and development from Orchid Chemicals and Pharmaceuticals 3,816,018 shares issued and outstanding after \$760,000 Orchid Chemicals and Pharmaceuticals investment through July 28, 2010. 7,140,378 shares issued and outstanding as of July 17, 2013.		
Additional Paid-in Capital	\$	71,17,030
Services Agreement from Owner	\$	-
Accumulated Deficit	\$	-1,09,44,146
Total Stockholders' Equity	\$	-38,27,116
Total Liabilities and Stockholders' Equity	\$	3,228

Diakron Pharmaceuticals Statements of Operations For the Period Apr'2020 to Mar'2021

Presented in U.S.Dollars Unaudited - Prepared by Management	Apr'2020-Mar'2021	
Expenses:		
Research & Development - Patents & Licenses	\$	227
License Impairment		
Accounting, Taxes, Legal Fees & Travel	\$	5,809
Consulting	\$	2,02,500
Office Expense	\$	50
Stock Option Compensation Expense		
Clinical Expenses	\$	44,962
Services from Owner Agreement - Amortized		
Other Expense / Interest Expense	\$	19,577
Total Expenses	\$	2,73,125
Other Income - Debt Settlement Income		
Net (Loss)	\$	-2,73,125